

**REMARKS**


The Official Action is a restriction requirement in which it is urged that there are three separate and distinct inventions claimed in this application. Applicants elect the Group II invention which includes claims 13-35 and 40, without traverse. Applicants have canceled the claims to the non-elected invention and reserve the right to file one or more divisional applications directed to the non-elected inventions at a later time.

Applicants have amended claim 40 to place this claim in proper independent form in view of the cancellation of claim 1 from the application. Applicants most respectfully submit that all of the claims remaining in the application are in full compliance with 35 USC 112 and an early action on the merits taking into consideration the prior art of record is now in order and is most respectfully requested.

It is further required in the Official Action that a single disclosed species be elected and the claims readable thereon be identified. Applicants elect the species of Compound C16 as disclosed at page 25 of the specification. Claims 13, 14, 17-20, 23-25 and 40 are readable on the elected species.

In view of the above comments and amendment to the claims, the election of the Group II invention, without traverse, and the election of species, an early and favorable action on the merits is now believed to be in order and is most respectfully requested.

Respectfully submitted,  
BACON & THOMAS, PLLC

By:   
Richard E. Fichter  
Registration No. 26,382

625 Slaters Lane, 4<sup>th</sup> Fl.  
Alexandria, Virginia 22314  
Phone: (703) 683-0500  
Facsimile: (703) 683-1080

REF:kdd  
A01.wpd

December 6, 2002

**Marked-Up Version of Changes Made**

**IN THE CLAIMS:**

Please replace claim 40 with the following amended claim 40.

40(Amended). A method of treating or preventing a disease condition caused or exacerbated by an MPV comprising the administration of an effective amount of a compound capable of facilitating the disruption of a chelated metal cation domain of a protein encoded for by an MPV gene to a mammal in need thereof, wherein said compound is a compound identified [in accordance with the method of claim 1] as a compound useful in the treatment of a disease or condition caused or exacerbated by an MPV by a method which comprises contacting a protein molecule containing a chelated metal cation domain, encoded by an MPV gene, with an effective amount of said compound for a time and under conditions sufficient to facilitate disruption of the chelated metal cation domain and directly or indirectly determining the amount of chelated metal cation released wherein the amount of chelated metal cation released is indicative of the disruption of the chelated metal cation domain.